GNH USA

Europe — EMA

Octreoscan (Indium In-111 Pentetreotide)

GNH USA supplies Octreoscan (Indium In-111 Pentetreotide), a somatostatin analog for neuroendocrine tumor imaging. Request a quote for global supply.

Indium In-111 Pentetreotide

Request sourcing

1
Pack/s

What is Indium In-111 Pentetreotide?

Indium In-111 pentacarbamoyl‑methyl‑DTPA‑octreotide (Indium In-111 pentetreotide), the active ingredient in Octreoscan, is a somatostatin analog presented as a diagnostic radiopharmaceutical for intravenous use. It binds to somatostatin receptors to help visualize neuroendocrine tumors and related lesions in patients undergoing evaluation.

GNH USA supplies Octreoscan as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

What is Indium In-111 Pentetreotide used for?

Octreoscan is a radiolabeled somatostatin analog used in diagnostic imaging of neuroendocrine tumor pathways. It assists clinicians in locating and staging disease. - Gastroenteropancreatic neuroendocrine tumors: enables whole‑body scintigraphic detection of somatostatin‑receptor positive lesions. - Bronchial and thymic carcinoids: highlights receptor‑rich tumors for surgical planning. - Metastatic disease assessment: determines extent of spread to guide therapeutic decisions.

What are the side effects of Indium In-111 Pentetreotide?

Adverse reactions are generally mild and related to the radiopharmaceutical or injection process.

Common Side Effects: - Nausea: transient feeling of queasiness after injection. - Flushing: brief warmth or redness of the face and neck. - Mild headache: short‑lasting discomfort. - Injection site pain: soreness at the venipuncture site. - Transient hypotension: temporary drop in blood pressure.

Serious or Rare Side Effects: - Severe allergic reaction (anaphylaxis): difficulty breathing, hives, or swelling. - Significant hypotension: prolonged low blood pressure requiring intervention. - Radiation‑induced marrow suppression: decreased blood counts. - Renal toxicity: impaired kidney function in susceptible patients.

What precautions apply to Indium In-111 Pentetreotide?

Octreoscan should be administered by qualified personnel in a setting equipped for nuclear medicine procedures. - Pregnancy: avoid use unless clearly needed, as radiation may affect fetal development. - Breastfeeding: discontinue breastfeeding for an appropriate period after administration. - Renal function: assess kidney function before use; adjust protocol if impairment is present. - Allergy history: verify no prior hypersensitivity to somatostatin analogs or indium‑111 compounds. - Storage: Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

What does Indium In-111 Pentetreotide interact with?

Octreoscan may interact with agents that affect somatostatin receptors or alter radiation distribution.

Major Interactions (Avoid): - Long‑acting somatostatin analog therapy (e.g., octreotide LAR): may compete for receptor binding and reduce imaging sensitivity.

Moderate Interactions (Monitor Closely): - Diuretics: can modify renal clearance of the radiotracer. - ACE inhibitors: may influence blood pressure response during injection. - Antihistamines: may mask early signs of an allergic reaction. - Radioprotective agents: could alter image quality if administered concurrently.

Frequently asked questions

What is Octreoscan used for?+
Octreoscan is a radiolabeled somatostatin analog used in nuclear medicine to image somatostatin‑receptor positive neuroendocrine tumors. It helps clinicians locate primary lesions, assess metastatic spread, and plan appropriate therapeutic strategies.
How does Indium In-111 pentetreotide work?+
Indium In-111 pentetreotide binds selectively to somatostatin receptor subtypes 2 and 5 on neuroendocrine cells. After intravenous injection, the complex is internalized and emits gamma photons that are captured by a gamma camera, producing detailed images of receptor‑rich tissues.
What is the usual dose of Octreoscan?+
The administered activity of Octreoscan is determined by the prescribing physician based on patient weight, age, and the imaging protocol. Dosage is individualized and should follow local regulatory and institutional guidelines.
Is Octreoscan safe during pregnancy or breastfeeding?+
Octreoscan involves a radioactive tracer, so it is generally avoided in pregnancy unless the diagnostic benefit outweighs the risk. Breastfeeding mothers should discontinue nursing for a period advised by the treating physician to prevent infant exposure.
How do I order Octreoscan from GNH USA?+
To request Octreoscan, submit an enquiry on the product page at gnh-usa.com specifying the required quantity. GNH USA works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and import documentation.
How does Octreoscan compare with other imaging agents for neuroendocrine tumors?+
Octreoscan (Indium‑111) is a well‑established agent for somatostatin‑receptor imaging, offering whole‑body scintigraphy. Newer PET agents such as Ga‑68 DOTATATE provide higher resolution and faster imaging, but Octreoscan remains useful where PET facilities are unavailable or for specific regulatory approvals.
What are the storage and handling requirements for Octreoscan?+
Octreoscan must be stored refrigerated at 2‑8 °C, protected from light, and should never be frozen or shaken. The product should be kept in its original container until ready for preparation and administration by qualified nuclear medicine staff.
How is Octreoscan administered?+
Octreoscan is administered intravenously by a trained nuclear medicine professional. After injection, patients typically wait a few hours before imaging to allow optimal tumor uptake and clearance of background activity.
What are the most serious risks associated with Octreoscan?+
Serious risks include severe allergic reactions (anaphylaxis), significant hypotension, radiation‑induced bone‑marrow suppression, and potential renal toxicity. Patients are monitored during and after injection to promptly identify and manage any adverse events.
Who should not use Octreoscan?+
Octreoscan is contraindicated in patients with known hypersensitivity to indium‑111 compounds or somatostatin analogs, and it should be avoided in pregnant women unless absolutely necessary. Caution is also advised for individuals with severe renal impairment or uncontrolled cardiovascular conditions.
Information provided on this page is for educational use by procurement and clinical professionals. Always consult a licensed healthcare provider for medical advice and prescribing decisions. GNH USA supplies this product subject to applicable regulatory and licensing requirements.
Send a sourcing enquiry for this product →

Product details

Drug
Indium In-111 Pentetreotide
Route
Intravenous Use
Manufacturer
Curium Netherlands B.V.
Origin
EU

Related products

Octreoscan

Octreoscan

Indium In-111 Pentetreotide

Curium Netherlands B.V.
EU
Octreoscan

Octreoscan

Indium In-111 Pentetreotide

Curium Belgium Bv
EU
Octreoscan

Octreoscan

Indium In-111 Pentetreotide

Curium Netherlands B.V.
EU
Octreoscan

Octreoscan

Indium In-111 Pentetreotide

Curium Netherlands B.V.
EU